Clinical trial · Observational
HRR Prevalence in LatAm PROSPECT Study
Prevalence of Homologous Recombination Repair (HRR) Gene Mutations in Patients With Metastatic Castration-resistant Prostate Cancer in Latin America: PROSPECT Study.
NCT04962880CI-TRIAL-00065646PROSPECTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Determine the prevalence of homologous recombination repair (HRR) gene mutations in participants with mCRPC in Latin America (LatAm) between February 2021 and January 2022.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Castration-resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Primary Outcome
- timeFrame
- Q1 2021 - Q1 2022
- description
- To know the prevalence and type of Homologous Recombinational Repair (HRR) mutations identified in Formalin-fixed paraffin-embedded (FFPE) tissue or blood samples in patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) in the selected participants countries in LatAm. A molecular test formulary would be completed when tissue sample is analyzed * Preservation time (years) * Origin of the FFPE (organ) * HRR mutation status (32 mutations would be analyzed and each of them would have as an answer "positive"/"negative"/"VUS") A molecular test formulary would be completed when blood sample is analyzed * Date of extraction (date) * HRR mutation status (32 mutations would be analyzed and each of them would have as an answer "positive"/"negative"/"VUS")
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participants aged≥18 2. Pathological mCRPC cases confirmed by histopathological report. 3. Evidence of a previous methastatic primary PC 4. Availability to provide medical history data(demographic information and history of cancer). 5. Availability to provide blood and/or tissue sample in case it is available 6. Participants who are able to sign the informed consent form(ICF). Exclusion Criteria: 1. Diagnosis of any severe acute or chronic medical or psychiatric conditions that may increase the risk associated with study participation or may interfere with the interpretation of the study results 2. Inability of participant to provide informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.